„The Product is the Process – Is it?“
Manufacturing and Translation of ATMPs and Tissue- & Cell-based products: 02-12-2026!
Dec. 2026|09:00 - 17:00 h
Investitionsbank des Landes Brandenburg (ILB), Potsdam, Babelsberger Straße 21, 14473 Potsdam
GSCN, bbb e.V., Paul Ehrlich Institut (PEI), the German ZLG, Health Capital - Cluster Healthcare Industries Berlin Brandenburg &
Berlin Partner
40 - 240 € (Participation fee: 240,00 €, a reduced participation fee of 50% applies to representatives of authorities. Please indicate your authority under „Remarks (Anmerkungen)“. Student participation fee: 40,00 €. Please indicate your matriculation number under „Remarks (Anmerkungen)“)
Register ➚ hehttps://biotech-verbund.de/veranstaltungen/the-product-is-the-process-is-it-2026-manufacturing-and-translation-of-atmp-and-tissue-cell-based-products/re
In regenerative medicine, cell or gene therapy: driven by remarkable research and clinical success, innovative therapy and product concepts for advanced therapy medicinal products (ATMPs) are in the focus of interest.
Several products have achieved marketing approval and some ATMPs even reached broad clinical application. In addition, a multitude of product approaches are in the early development phase or in clinical trials. Concomitantly, a complex and dynamic regulatory environment has emerged in this modern biotechnological area.
Program:
Dr. Ralf Sanzenbacher, Paul-Ehrlich-Institut, Langen, Germany
"Welcome address"
Prof. Agnete Kirkeby, PH.D., University Copenhagen
„Human pluripotent stem cell products in the clinic“
Prof. Georg Schott, Ph.D., Friedrich-Alexander-University Erlangen-Nürnberg and University Clinic Erlangen, German Center for Immunotherapy, Erlangen:
„Immunotherapeutic strategies for autoimmune diseases: Current status and future trends“
Pierre Springuel, Ph.D., Cell and Gene Therapy Specialist, Sartorius:
„Cell therapy platform development: From design to qualification“
Vaneet Sabharwal, Ph.D., Thermo Fisher Scientific Life Technologies:
„Beyond reagents: Building a robust raw material strategy for advanced therapies“
Marija Brgles, Ph.D., Boehringer Ingelheim Pharma GmbH & Co. KG:
„Structural complexity and heterogeneity of virus-based therapeutics: Does the process define the product? Insights from VSV-GP manufacturing“
Csaba Miskey, Ph.D., Paul-Ehrlich-Institut, Langen, Germany:
„Digging deep: Advanced sequencing technologies for characterization of ATMPs: Strengths and limitations“
Prof. Gerald Schumann, Ph.D., Paul-Ehrlich-Institut, Langen, Germany:
„Genomic integrity in cell and gene therapy: Risk factors and product control“
All speakers and presentation titles are confirmed, changes possible if necessary.
Register ➚ here
↓ Flyer Download